Relaps / Refrakter Alk Negatif Sistemik Anaplastik Büyük Hücreli Lenfoma Tedavisi: Kemoterapiden Hdac İnhibitörlerine Uzanan Bir Vaka

Zhang XR, Chien PN, Nam SY, Heo CY. Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment. Cancers (Basel). 2022 Mar 24;14(7):1650. doi: 10.3390/cancers14071650. PMID: 35406421; PMCID: PMC8997054.

Laurent, C.; Baron, M.; Amara, N.; Haioun, C.; Dandoit, M.; Maynadié, M.; Parrens, M.; Vergier, B.; Copie-Bergman, C.; Fabiani, B.; et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients from the French Lymphopath Network. J. Clin. Oncol. 2017, 35, 2008–2017.

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253. doi:10.1182/blood.2022015851.

Xie W, Medeiros LJ, Fan G, Li S, Xu J. Systemic ALK-negative anaplastic large cell lymphoma: Insights into morphologic, immunophenotypic, genetic and molecular characteristics. Hum Pathol. 2025 Feb;156:105671. doi: 10.1016/j.humpath.2024.105671. Epub 2024 Oct 17. PMID: 39424106.

Pina-Oviedo S, Ortiz-Hidalgo C, Carballo-Zarate AA, Zarate-Osorno A. ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas. Cancers (Basel). 2021 Sep 17;13(18):4667. doi: 10.3390/cancers13184667. PMID: 34572893; PMCID: PMC8472588.

Frutos Díaz-Alejo J, Prieto-Potín I, Manso R, Rodríguez M, Rebollo-González M, Díaz de la Pinta FJ, Morales-Gallego M, Rodríguez-Pinilla SM, Onaindia A. Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype. Int J Mol Sci. 2025 Jun 19;26(12):5871. doi: 10.3390/ijms26125871. PMID: 40565334; PMCID: PMC12192600.

Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. PMID: 34921960; PMCID: PMC9447792.

O'Connor OA, Ko BS, Wang MC, Maruyama D, Song Y, Yeoh EM, Manamley N, Tobinai K. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2024 Jun 11;8(11):2601-2611. doi: 10.1182/bloodadvances.2023010441. PMID: 38429077; PMCID: PMC11157204. Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023 Nov 1;129(21):3372-3380. doi: 10.1002/cncr.34974. Epub 2023 Aug 10. PMID: 37560925.

O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22. PMID: 26101246; PMCID: PMC5087312.

Allen PB, Lechowicz MJ. Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas. Cancer Manag Res. 2018 Dec 6;10:6731-6742. doi: 10.2147/CMAR.S149241. PMID: 30584367; PMCID: PMC6289206.

Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. doi: 10.1200/JCO.2011.37.4223. Epub 2012 Jan 23. PMID: 22271479.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Erratum in: Blood. 2018 Jul 26;132(4):458-459. doi: 10.1182/blood-2018-05-853192. PMID: 28974506; PMCID: PMC5746164.

U.S. Food and Drug Administration. Withdrawn Cancer Accelerated Approvals. Romidepsin for peripheral T-cell lymphoma after at least one prior therapy; withdrawal date: July 30, 2021.